Category: Intellectual property
-
Start-Up Formed to Develop Non-Opioid Pain Drugs
A new enterprise is being formed to develop non-addictive drugs for chronic pain that use different biochemical processes than opioid pain relievers.
-
RNA Meds Companies Partner on Human, Animal Vaccines
Synthetic Genomics Inc. and Arcturus Therapeutics Inc. are collaborating on longer-lasting and more robust RNA therapies and vaccines for humans and animals.
-
Univ. Lab, Company Broaden Bacterial Vaccine Impact
Researchers from University at Buffalo and a campus spin-off enterprise devised a way to expand the scope of anti-bacterial vaccines, as shown in tests with lab animals.
-
Lilly, CureVac Partner on RNA Cancer Drugs in $1.8B Deal
Drug maker Eli Lilly and Company and biotechnology company CureVac AG agreed to develop a series of cancer immunotherapies based on CureVac’s messenger RNA technology.
-
Roche, Biotech to Discover New Antibiotics
A biotechnology company that discovers new drugs through detailed genomic analysis is partnering with drug maker Roche to find new treatments for bacterial infections that resist current antibiotics.
-
Biotech Licenses Gene Editing for Autoimmune Disorders
A company developing therapies with gene editing technologies is acquiring a new form of gene editing on T-cells in the immune system to treat autoimmune diseases.
-
Patent Awarded for Live Bacterial Acne Treatment
A company developing treatments for disease by restoring the natural balance of bacteria on the skin received a patent for its acne therapy using spray-on live bacteria.
-
Drug Delivery Technology Licensed in $2B Deals
The biotechnology company Halozyme Therapeutics Inc. is licensing its technology for making infusion drugs deliverable with injections to two more drug makers.
-
AstraZeneca, Biotech Partner on Messenger RNA Therapies
Global drug maker AstraZeneca is acquiring an option to license the rights to a technology based on genetic material transcribed from DNA, for new respiratory disease treatments.
-
Patent Set for Peptide Nerve Damage Treatments
The European Patent Office announced its intent to award a patent on treatments for nerve cell damage based on the peptide thymosin beta 4.